Medtronic plc announced that 12-month data from the TITAN 2 pivotal clinical trial of its Altaviva implantable tibial neuromodulation device for urge urinary incontinence are now available online in The Journal of Urology. The company reported that all primary and secondary endpoints were met, including about 20 percent of patients with no urge urinary incontinence episodes at 12 months, 61 percent maintaining at least a 50 percent reduction in daily episodes, and 80 percent reporting improvement on the Patient Global Impression of Improvement scale. Medtronic said 24-month TITAN 2 data will be presented at the 2026 Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Conference on February 28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.